Fenwick Represents Dermira in Pending $1.1 Billion Acquisition by Lilly

Fenwick & West is representing Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions, in its definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction. The transaction is expected to close by the end of the first quarter of 2020, subject to customary closing conditions. More information about the acquisition can be obtained from the company announcement.

The transaction team includes corporate partners Doug Cogen and David Michaels, and associates Victoria Lupu, Katherine Duncan, Jennifer Hitchcock, Janiece Jenkins, Lillian Icard and Carson Jackson; executive compensation and employee benefits partners Matthew Cantor, Scott Spector and Elizabeth Gartland, counsels Nicholas Frey and Laura McIntyre, and associate Grace Strickland; employment practices partner Daniel McCoy; technology transactions partner Stefano Quintini and associates Sophia Chen and Sang Kwon; intellectual property partner Daniel Becker; antitrust and trade regulation partner Mark Ostrau; and tax partner William Skinner and associate Ora Grinberg.